Introduction
The T-cell arm of the immune system plays an important role in the defence against viruses and virus-induced tumours [ 1,2]. Virus-induced tumours can be eradicated by both CD8' cytotoxic T-lymphocytes (CTLs) and CD4+ T-helper lymphocytes (Th-cells) [ 1-31. These T-cells recognize antigenic peptides processed from viral (0nco)proteins or other tumour antigens that are presented in the context of major histocompatability complex (MHC) glycoproteins. By and large, MHC class I molecules present antigenic peptides to CTL, whereas Th-cells recognize antigenic peptides in the context of MHC class I1 molecules. In general, it seems that the major effector subset of tumour-specific T-cells responsible for rejection of tumours is confined to CD8+ CTLs [l-31. There is now increasing evidence that both virally and non-virally induced tumours can be antigenic in the sense that they are recognized by tumour-specific CTLs [4-61. Nonetheless, it is obvious from the progressive growth of many cancers that tumours are able to dodge T-cell recognition and destruction. Therefore, adequate stimulation of the immune system is important in order to provide the recipient with an effective antitumour response. This might be achieved by infusion of in vitro expanded, activated tumour-specific T-cells, by active immunization with genetically modified tumour cells or by immunization with vaccines containing genes, proteins or antigenic peptides derived from tumour antigens [ 1-81. Here, we shall attempt briefly to summarize our findings and discuss how they might lead to establishing new modalities for specific immune intervention of cancer.
lmmunotherapy of virus-induced tumours by adoptive transfer of cloned CTLs
An approach to be considered for enhancement of specific anti-tumour immunity, especially in Abbreviations used: CTL, cytotoxic T-lymphocyte; HPV, human papillomavirus; MHC, major histocompatibility complex; TAP, transporter associated with antigen presentation. Another mechanism that a tumour cell may employ to escape from CTL-mediated recognition is hindering the presentation of a CTL epitope to the immune system. Tumour cells transformed by the Ad5E1 region and an activated EJrus oncogene are, unlike tumour cells transformed by the AdSE 1 region only, tumorigenic in immunocompetent mice, despite the fact that they harbour at least two CTI, epitopes that can mediate tumour regression [ 161. Apparently, these tumour cells escape from CT1,-mediated killing in vivo. Interestingly, AdSEl+ rus-transformed tumour cells are not lysed by AdSElB-specific CTI, clones in vitro [16] . In vivo, adoptively transferred AdSE 1B-specific CTL clones were not able to eradicate AdSEl+ rustransformed tumours, although they could delay the growth rate of the tumour (R. E. M. Toes, R. J. J. Hlom, R. Offringa, C. J. M. Melief and W. M. Kast, unpublished work). The failure of the AdSElBspecific CTI, clones to lyse AdSE1 + ras cells is not due to reduced protein levels of either MHC class I or AdSElH, since the levels of expression of these proteins were similar to the levels of expression of MHC class I or AdSElB protein in AdSEl-transformed tumour cells. This suggests that the action of the EJrm oncogene affects the presentation of the AdSE 1B-encoded CTI, epitope at the post-translational level. Activated rus oncogenes have been strongly implicated in the development of human cancer [23] . Modulation of the presentation of T-cell epitopes by a rus-induced mechanism might be helpful for the tumour to escape from immune surveillance.
Escape of tumours from T-cell surveillance
Additionally, other mechanisms might be used by the tumour to escape from CTL-mediated killing. Tumours transformed by the oncogenic human adenovirus type 12 express a low level of MHC class I molecules on their cell surface [24] . This might be explained by an inefficient transcription of MHC class I genes and genes encoding the transporter associated with antigen presentation (TAP) [2S,26] . TAP-1 and -2 proteins are important for the delivery of antigenic peptides to MHC class I molecules ([27] and references therein). Down-regulation of MHC class I and/or TAP can lead to an escape of the tumour from CTL-mediated lysis. This feature has also been observed in human tumours. For instance, in paraffinembedded cervical carcinoma samples derived from patients a congruent loss of TAP-1 and MHC class I expression was detected, indicating that inhibition of peptide transport by down-regulation of TAP is a potential strategy for cervical carcinoma cells to escape from CTL-mediated killing [28] .
Identification of tumour-associated CTL epitopes
The goal of vaccination against tumours is the induction of protective anti-tumour immunity. Many different approaches are currently being explored in order to stimulate the generation of tumour-specific effector T-cells ([ 1-81 and references therein). In our laboratory, the possibilities of establishing protective anti-tumour immunity by vaccination with free synthetic peptides representing minimal CTL epitopes are explored. The identification of such peptides can be done by mapping the epitopes of tumour-specific T-cells isolated from tumour-bearing individuals. Boon [6] revealed the identity of several tumour-associated CTL epitopes recognized by tumour-reactive CTI, clones derived from cancer patients through molecular cloning. Alternatively, peptides derived from tumour antigens can be identified on the basis of their capacity to bind to MHC class I molecules [29, 30] . The ability to predict if a peptide binds to a certain MHC class I molecule on the basis of an MHC class I binding motif and the development of computer programs utilizing such motifs for the prediction of MHC class I binding peptides may greatly facilitate that search [31-341. It is now well established that the binding affinity of a peptide for a MHC class I molecule has a strong impact on its immunogenicity [35-371. The approach of selecting peptides bearing MHC class I-binding motifs for a certain MHC molecule, and testing their ability to elicit primary CTLs that cross-react with tumour cells, seems to be successful [10, 37] . In this way, peptides can be selected that can be incorporated in peptide-based T-cell vaccines.
Induction of CTL responses by peptide vaccination
An advantage of the use of short synthetic peptides as opposed to other vaccination strategies is that peptides can selectively stimulate the T-cell specificity of choice. In this manner it should be feasible to activate CTLs that recognize subdominant and immunodominant CTL epitopes expressed by the same tumour. A possible complication of immunization with soluble peptides is that they can also bind to MHC molecules of 'non-professional' antigen-presenting cells, and this may lead to the induction of anergy or exhaustion. Indeed, peptideinduced T-cell tolerance and unresponsiveness has been described in several models . However, in all these cases relatively high doses of peptide were administered [38-411. Protective peptide-induced CTL-mediated immunity was first described in two viral murine models [42, 43] . The first data describing peptideinduced anti-tumour immunity came from studies using a polyoma-induced tumour [44] . Immunity against polyoma-induced tumours was established by immunizing mice with synthetic peptides corresponding to sequences of polyoma virus T-antigens. However, the immunity introduced by the vaccinating peptides was not as efficient as vaccination with polyoma virus and not sufficient to induce a complete rejection of a small inoculum of polyoma tumour cells [44] .
The first demonstration that peptides with a high affinity for binding to MHC class I molecules can be successfully used for vaccination purposes came from studies in a human papillomavirus type 16 (HPV 16)-induced murine tumour system [45] . A synthetic peptide deduced from the HPV 16 E7 protein was identified by its ability to bind with high affinity to the murine H-2Db molecule. Immunization of B6 mice with this peptide induced a CTL response that cross-reacted on HPV 16-transformed tumour cells and target cells infected with a recombinant vaccinia virus construct expressing HPV 16 E7 [45, 46] . More importantly, vaccination of B6 mice with this HPV 16 E7-encoded synthetic peptide induced efficient protection against a challenge with a lethal dose of HPV 16-transformed tumour cells [45] .
Identification of HPV 16 E6 and E7-encoded human CTL epitopes
Encouraged by these results, the identification of potential human CTL epitopes derived from the HPV 16 E6 and E7 oncoproteins was undertaken. Identification of such CTL epitopes is of interest, because HPV infection, and especially the HPV 16 E6 and E7-encoded oncoproteins, has been implicated in the cervical carcinogenesis [48] . The risk of developing cervical cancer and other HPV-related warts or cancers is higher in individuals with an impaired cellular immune response, suggesting a role for the immune system in preventing the appearance of HPV-related dysplasias [49, 50] . In this respect it is important to note that, for example, an HPV 11 E7-encoded peptide endogenously processed in cells infected with HPV 11 E7-expressing vaccinia constructs was recognized by CTLs. This shows that CTLs are indeed able to react against endogenously processed peptides derived from HPV [51] . Peptide-MHC class I affinity binding studies identified peptides deduced from the sequences of HPV 16 E6 and E7 that bound to human MHC class I molecules [30] . Peptides capable of binding to the human leucocyte antigen A*0201 (HLA-A2) were selected for in vitro and in vivo immunogenicity studies [37] . At least three peptides with high affinity of binding to the HLA-A2 molecule were able to induce in vitro CTL responses in peripheral blood lymphocytes from healthy donors. CD8+ CTL clones derived from these bulk cultures were MHC class I restricted and lysed a human HLA-A2+ HPV 16+ cervical carcinoma cell line, suggesting that these peptides represent naturally processed CTL epitopes [ 371. These peptides also elicited a strong CTL response in mice transgenic for the antigen-presenting domains of the HLA-A2 molecule, showing that these peptides are able to induce CTL-mediated immunity in vivo.
Taken together, these data indicate that peptides representing minimal CTL epitopes offer a promising approach for the development of effective anti-cancer vaccines. In our hospital, the first CTL epitope-based peptide vaccine is now being employed in a trial in which the effects on patients with HPV 16-induced cervical cancer are evaluated.
Epilogue
The recent progress made in the field of human tumour immunology and murine tumour model systems boosts the development of anti-tumour vaccines and other immune intervention strategies. In several murine model systems, it has been shown that established tumours can be eradicated by tumour-specific CD8' T-cell clones, and the first example of successful adoptive transfer in humans has been described [52] . Although this was performed with cytomegalovirus-specific CD8 + CTL clones and not with tumour-specific CTL clones, it clearly shows that large numbers of antigen-specific clonal T-cells can be generated and infused back into patients without severe side-effects [ 521. Effective peptide-based vaccines are able to induce protective tumour-specific immunity in mice, and the efficacy of such vaccines is now being explored in Volume 23 the clinic. Nonetheless, the varied and diverse strategies tumours use to escape from T-cell-mediated recognition might hamper such therapeutic formulations. The development of methods that prevent the tumour escaping from immune attack will be of the utmost importance before immunotherapy can become part of the established armamentarium used to fight cancer. 
